Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
 1 a 20 de 174 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Kunchok A, Aksamit Jr AJ, Davis III JM, Kantarci OH, Keegan M, Pittock SJ, Weinshenker BG, McKeon A. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurology 2020:18 de mayo. [Ref.ID 103656]
2. Cita con resumen
Esse S, Mason KJ, Green AC, Warren RB. Melanoma risk in patients treated with biologic therapy for common inflammatory diseases. A systematic review and meta-analysis. JAMA Dermatol 2020:20 de mayo. [Ref.ID 103629]
3. Cita con resumen
Taylor P. BMS completes Celgene merger after FTC okay. PMLiVE 2019:18 de noviembre. [Ref.ID 103210]
4. Cita con resumen
Khan R, Nugent CM, Scaffidi MA, Gimpaya N, Grover SC. Association of biologic prescribing for inflammatory bowel disease with industry payments to physicians. JAMA Intern Med 2019;179:8 de julio. [Ref.ID 103170]
5.Enlace a cita original Cita con resumen
Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol 2019:10 de mayo. [Ref.ID 103131]
6. Cita con resumen
Silverman E. STAT Plus: AbbVie is sued for using Humira patent deals to block competition in the U.S.. STAT Daily Recap 2019:20 de marzo. [Ref.ID 103062]
7.Enlace a cita original Cita con resumen
Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;378:24 de mayo. [Ref.ID 102636]
8.Enlace a cita original Cita con resumen
Yong HY, McKay KA, Daley CGJ, Tremlett H. Drug exposure and the risk of multiple sclerosis: a systematic review. Pharmacoepidemiol Drug Saf 2018;27:febrero. [Ref.ID 102630]
9. Cita con resumen
Anónimo. Baricitinib et polyarthrite rhumatoïde. Prescrire 2018;38:171-2. [Ref.ID 102586]
10. Cita con resumen
Wadström H, Frisell T, Askling J, for the Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice. A nationwide cohort study from Sweden. JAMA Intern Med 2017;177:1605-12. [Ref.ID 102143]
11. Cita con resumen
Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017;318:1679-86. [Ref.ID 102138]
12. Cita con resumen
Pinto RZ, Verwoerd AJH, Koes BW. Which pain medications are effective for sciatica (radicular leg pain)?. BMJ 2017;359:j4248. [Ref.ID 102095]
13. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
14. Cita con resumen
Smolen JS, Burmester G-R, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Gervitz L, Ionescu L, Peterson L, Fleischmann R. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 2016;388:2763-74. [Ref.ID 101029]
17. Cita con resumen
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023-38. [Ref.ID 100911]
18. Cita con resumen
Anónimo. Ustékinumab et psoriasis chez les adolescents. Prescrire 2016;36:733-4. [Ref.ID 100889]
19. Cita con resumen
Seleccionar todas
 
 1 a 20 de 174 siguiente >>